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Regulation of proteolysis is a critical element of the host
immune system and plays an important role in the induction of
pro- and anti-inflammatory reactions in response to infection.
Some bacterial species take advantage of these processes and
recruit host proteinases to their surface in order to counteract
the host attack. Here we show that Thrombin-activatable
Fibrinolysis Inhibitor (TAFI), a zinc-dependent procarboxypep-
tidase, binds to the surface of group A streptococci of an M41
serotype. The interaction is mediated by the streptococcal col-
lagen-like surface proteins A and B (SclA and SclB), and the
streptococcal-associated TAFI is then processed at the bacterial
surface via plasmin and thrombin-thrombomodulin. These
findings suggest an important role for TAFI in the modulation
of host responses by streptococci.
Streptococcus pyogenes is an important human Gram-posi-
tive pathogen that mainly causes throat and skin infections.
Although these conditions are normally superficial and self-
limiting, they can occasionally turn into invasive and life-
threatening diseases such as sepsis and necrotizing fasciitis (1).
In order to colonize the human host, S. pyogenes expresses so-
called adhesins, which allow the bacterium to attach to the
extracellular matrix or to cell surface structures. So far, at least
20 adhesins have been described in S. pyogenes, including for
instanceMproteins and protein F1 (for a review see Ref. 2). The
two related streptococcal collagen-like surface proteins SclA
and SclB, which were first described in 2000 and 2001, also
belong to this family (3–7). Although their extracellular parts
differ in size andprimary sequence, SclA and SclB are organized
into a similar “lollipop”-like structure. The stalk is made up of a
collagen-like region with varying numbers of GXY repeats,
whereas the globular head consists of a non-collagenous ami-
no-terminal variable region. Both proteins have a conserved
signal peptide and a carboxyl-terminal region that is attached to
the cell wall via an LPATG anchor. The collagen-like regions of
Scls have been shown to mediate adhesion to human lung epi-
thelial cells (5) and fibroblasts (4). It has also been reported that
SclA fromM type 41 activates the collagen receptor 21 inte-
grin on fibroblasts (8) and interacts with the low density
lipoprotein in human plasma (9).
Proteolysis plays an important role in host parasite interac-
tions. Although some immune defense mechanisms such as
complement, coagulation, and fibrinolysis are dependent on
their activation by limited proteolysis, bacteria have evolved
strategies to benefit from these host systems by assembling host
proteinases at their surface. Probably the best studied interaction
in this respect is the binding of plasmin(ogen) to the bacterial sur-
face,which is thought tobe amechanism for thebacteria to trigger
their dissemination in the human host (10).
Thrombin-activable fibrinolysis inhibitor (TAFI),2 also
known as procarboxypeptidase B, procarboxypeptidase R, and
procarboxypeptidase U, is an arginine- and lysine-specific pro-
carboxypeptidase. The protein is synthesized in the liver and
secreted into plasma, where it circulates as a zymogen at con-
centrations between 60 and 275 nM (11). Themost potent acti-
vator of TAFI is the thrombin-thrombomodulin complex
(12), but plasmin, trypsin, and neutrophil elastase have also
been reported to function as activators (13–15). Active TAFI
(TAFIa) has anti-fibrinolytic properties as the enzyme
removes carboxyl-terminal lysine residues from fibrin,
thereby attenuating accelerated plasmin formation. Apart
from its role in regulating fibrinolysis, TAFI can also modu-
late inflammatory responses. For instance, TAFIa has been
shown to inactivate the anaphylatoxins C3a and C5a by
removing their carboxyl-terminal arginine residues (16), and
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it has been suggested that TAFI is involved in the conversion
of the fibrinopeptide B (FPB), a potent neutrophil chemoat-
tractant, to its inactive metabolite des-Arg FPB (17). In
another study, it was found that the removal of the carboxyl-
terminal arginine from thrombin-cleaved osteopontin by
TAFI impairs the adhesive function of the protein (18).
Moreover, TAFI also has pro-inflammatory properties,
because it can convert bradykinin into desArg9bradykinin, a
selective agonist of the kinin B1 receptor, which has an
important role in chronic inflammatory processes (16, 19).
However, the pathophysiological effects of these modifica-
tions are not completely understood.
The present study was undertaken to investigate the interac-
tion between TAFI and S. pyogenes. Here we find that strepto-
cocci of serotype 41 are able to bind TAFI and that activation of
TAFI can occur on the bacterial surface, which might be an
important mechanism for bacteria to modulate inflammatory
reactions of the host.
EXPERIMENTAL PROCEDURES
Reagents—TAFI and PAB were produced and purified as
described elsewhere (20, 21). Plasminogen and plasmin were
purchased from Sigma, and thrombin was from Chemicon,
Malmö, Sweden. Oligonucleotides were obtained from DNA
Technology A/S, Aarhus, Denmark. Rabbit lung thrombo-
modulin was purchased from American Diagnostica (Green-
wich, CT), hippuryl-arginine and H-D-Phe-Pro-Arg-chlorom-
ethylketone from Bachem (Bubendorf, Switzerland), and
potato carboxypeptidase inhibitor from Calbiochem (La Jolla,
CA). For the TAFI activity assays, thrombinwas used that was a
generous gift from Dr. W. Kisiel (University of New Mexico,
Albuquerque,NM),while plasmin and t-PA (actilyse)were pur-
chased from Roche Applied Science.
Bacteria and Culturing Conditions—S. pyogenes AP strains,
obtained from the Institute of Hygiene and Epidemiology (Pra-
gue, Czech Republic), were grown in Todd-Hewitt broth (BD
Biosciences) in 5% CO2 at 37 °C. To express SclA and SclB
recombinantly, the Escherichia coli strain BL21 Star (DE3) was
used. Bacteria were grown in Luria Bertani broth (1% (w/v)
tryptone (BDBiosciences), 0.5% (w/v) yeast extract (Oxoid Ltd.,
Basingstoke,Hampshire, UK), and 1% (w/v)NaCl (Merck), sup-
plemented with 1% (w/v) glucose (Prolabo, Fontenay sous bois
Cedex, France) and kanamycin 50 g/ml (Sigma).
Radiolabeling—Proteins were labeled with 125I with Iodo-
Beads (Pierce) according to the manufacturer’s instructions.
Binding Assays—Overnight cultures of bacteria were washed
three times in PBS with 0.02% sodium-azide and 0.05% Tween,
adjusted to 0.02–2  109 CFU/ml, and incubated with 40,000
cpm of 125I-labeled TAFI, plasmin, or thrombin for 1 h at room
temperature. Bacteria werewashed once in PBS, 0.02% sodium-
azide and 0.05% Tween, and the radioactivity of the cell pellets
was detected with a  counter (PerkinElmer). For competition
experiments, AP41 bacteria (1  107 CFU/ml) were incubated
with 50,000 cpm of 125I-TAFI in the presence or absence of 40
g/ml rSclA/AP/M41, rSclB/AP/M41, or protein PAB. Alter-
natively, bacteria were incubated with 50,000 cpm of 125I-plas-
min or 125I-thrombin in the absence or presence of 12.5–100
g/ml of unlabeled plasmin or 100–800 g/ml of unlabeled
thrombin, respectively. Bacteria were washed, and bound 125I-
labeled ligand was determined as above.
Protein Sequence Analysis—TAFI was coupled to CNBr-ac-
tivated Sepharose 4B (Pharmacia Biotech, Sollentuna, Sweden)
according to the protocol provided by the manufacturer. Sur-
face proteins of S. pyogenes AP41 were removed by cleavage
with CNBr as described (22). Briefly, bacteria were washed and
resuspended in PBS (2 ml of PBS/g bacteria, wet weight) and
mixed with an equal volume of CNBr 30 mg/ml in 0.2 M HCl.
After incubation for 15 h on rotation at room temperature, cells
were pelleted by centrifugation. The supernatant was filter-
sterilized, dialyzed against 0.1 M HCl, neutralized with 1.5 M
Tris-HCl, pH 8.8, and finally incubated with TAFI-coupled
Sepharose at 4 °C overnight. After extensive washing, bound
proteins were eluted with 0.1 M glycine-HCl, pH 2.0. Eluted
fractions were examined by SDS-PAGE, and protein bands
were excised and sent to Eurosequence (Groningen, The Neth-
erlands) for identification by internal sequencing. The peptide
sequences generated by internal sequencing were matched
against streptococcal proteins in a BLAST search.
PCR and Sequencing—Genomic DNA was obtained by boil-
ing bacteria in H2O for 5 min. PCR was performed in aMaster-
cycler (Eppendorf) using Taq polymerase and buffers from
Saveen&Werner AB (Malmö, Sweden). dNTPswere from Fer-
mentas (Burlington, Ontario, Canada). Sequencing was per-
formed using BigDye Terminator v3.1 kit (Applied Biosystems,
Foster City, CA) according to the manufacturer’s protocol.
Primers with the following sequences were used: SclA forward,
CAA CAT ATG TTG ACA TCA AAG CAC, SclA reverse,
GGGTTGGATCCCTAACCAGTTGCTG; SclB forward 1,
ATA CAA AAA GAA CTT TAC AAT CAT TC, SclB forward
2, CTT AAA GAG TTA AAT ATG TTT G, and SclB reverse,
GAT TGG ATC CTT AGC CTG TTG CTG GC.
Recombinant Protein Expression—SclA and SclB from the
AP41 strain were PCR-amplified with the following primer
pairs: SclA forward, CACCGATATCTGGGACCAGGAGC,
SclA reverse, GCTCTCAAGTTGCTGGTAGACGTC; SclB
forward, CAC CGA TGG CGA AGG TAT CAG AAA G, and
SclB reverse, GTT TCT CAT GTT GCT GGC AAT TG. The
PCR products were cloned into the pET200 TOPO vector
(Invitrogen), resulting in His-tagged fusion proteins. The vec-
tor was amplified in E. coli TOP 10 cells and then transformed
into E. coli of the BL21 Star (DE3) strain for protein expression.
Recombinant proteins were purified on nickel-nitrilotriacetic
acid His-Bind-Sepharose (Novagen, Madison, WI). Recombi-
nant SclA from the M41 strain MGAS6183 and rScls from the
M28 strain MGAS6274 were produced and purified as
described previously (23).
Slot Blot Analysis—Different amounts of recombinant SclA
and B from different strains were applied to the wells of a Mil-
liBlot (Millipore Corp., Billerica, MA) and transferred to a
methanol-activated Immobulone Transfer Membrane (Milli-
pore) by gentle suction. After blocking in VBS buffer (140 mM
NaCl, 5 mM sodium-5.5-diethylbarbiturate, pH 7.35) supple-
mented with 0.25% (w/v) gelatin and 0.25% (v/v) Tween 20 for
4  10 min, the membrane was incubated with 125I-labeled
TAFI (2  105 cpm/ml) in VBS with 0.1% (w/v) gelatin over-
night at 4 °C. The membrane was then washed in PBS 0.25%
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(w/v) gelatin and 0.25% (v/v) Tween 20 and exposed to an x-ray
film (AGFA, Mortsel, Belgium) for 10 days.
Binding Studies Using a BIAcore 2000 Biosensor System—Re-
combinant AP41 SclA and SclB were immobilized to a CM5
sensor chip using the amine coupling kit according to the sup-
plier’s recommendation (Biacore AB). SclA and SclB were
applied in 10 mM NaAc, pH 3.1. Immobilization of SclA on the
chip resulted in an increase of the resonance signal by 400
resonance units and with SclB of 440 resonance units. Bind-
ing studies were done using 10 mM Hepes, 150 mM NaCl,
0.005% P20, pH 7.4, at a flow rate of 30 l/min at 25 °C. Differ-
ent concentrations of TAFI (0–2 M) were injected for 3 min.
The KD values were calculated using the steady-state model in
the BiaEvaluation software.
TAFI Cleavage—125I-labeled TAFI (2  106 cpm/ml) was
incubated in the absence or presence of S. pyogenes AP41 bac-
teria (1 108 CFU/ml in PBS containing 0.25% (v/v) Tween 20,
final concentration) together with different concentrations of
thrombin and thrombomodulin (5–100 nM of each protein) at
37 °C for 10 min or with plasmin (0.5–10 g/ml) at 37 °C for 20
min. Bacteria were then washed once in PBS with 0.25% (v/v)
Tween 20, resuspended in SDS sample buffer (125 mM Tris, 4%
(w/v) SDS, 10% (v/v) glycerol, 10% (v/v) 2-mercaptoethanol,
2‰ (w/v) Bromophenol blue), and boiled for 5 min. Cells were
removed by centrifugation, and the supernatants were sepa-
rated on an SDS-PAGE gel along with the samples incubated
without bacteria. The gels were dried and exposed to x-ray film.
Alternatively, AP41 bacteria (1  108 CFU/ml in PBS contain-
ing 0.25% (v/v) Tween 20, final concentration) were preincu-
bated with thrombin-thrombomodulin (100 nM of each pro-
tein) or plasmin 10g/ml for 1 h on ice.Unboundproteinswere
removed by a washing step. Bacteria were then incubated with
125I-TAFI (200,000 cpm) at 37 °C for 15min (thrombin-throm-
bomodulin) or 30 min (plasmin) followed by a centrifugation
step. Supernatants were collected, and cell pellets were subse-
quently washed and resuspended in SDS sample buffer as
described above. Supernatants and proteins recovered from the
bacterial pellets were separated on SDS-PAGE gels and ana-
lyzed as described above.
Negative Staining Transmission Electron Microscopy—SclA,
SclB, and TAFI, as well as TAFI in complex with SclA or SclB,
were analyzed by negative staining and electron microscopy as
described previously (24). TAFI and rScls were mixed in Tris-
buffered saline and allowed to react for 30 min at 4 °C. Final
sample concentrations were 20 nM in 50 mM Tris-HCl, 0.15 M
NaCl, pH 7.4 (Tris-buffered saline). Subsequently, 5-l aliquots
were adsorbed onto carbon-coated grids for 1min, washedwith
two drops of water, and stained on two drops of 0.75% uranyl
formate. The grids were rendered hydrophilic by glow dis-
charge at low pressure in air. Specimens were observed in a Jeol
JEM 1230 electron microscope operated at 60 kV accelerating
voltage. Images were recorded with a Gatan Multiscan 791
CCD camera.
Determination of the Stability of TAFIa in the Presence of
rScls—The assay was basically done as described (25). To deter-
mine the effect of the presence of rSclA/AP/M41 and rSclB/AP/
M41 on the rate of TAFIa inactivation, TAFI (12.5 nM) (all con-
centrations are final concentrations) and rScls (0–0.18 M)
were added to a premix of thrombin (16 nM) and thrombo-
modulin (32 nM) in the presence of CaCl2 (5 mM), in 20 mM
Hepes, pH 8.0/0.1%, bovine serum albumin. This mixture was
incubated for 1 min at 37 °C before the thrombin activity was
stopped by adding H-D-Phe-Pro-Arg-chloromethylketone,
while the mixture remained at 37 °C to allow spontaneous
TAFIa inactivation. At several time points, 20-l samples were
withdrawn and added to 50 l of the substrate hippuryl-argi-
nine (21.4mM). After 30min of incubationwith the substrate at
37 °C, substrate conversion was stopped by adding 50 l of 1 M
HCl. Then, o-methyl hippuric acid (1.7 M) was added as an
internal standard, both o-methyl hippuric acid and hippuric
acid were extracted using a Solid Phase Extraction unit accord-
ing to the supplier’s recommendation (Waters Oasis, Wexford,
Ireland), and samples were analyzed by high pressure liquid
chromatography as described (25). The TAFIa activity is
expressed in units/liter. One unit of enzyme activity was
defined as the amount of enzyme required to hydrolyze 1 mol
of substrate/min at 37 °C under the conditions described (25).
Influence of Scls on TAFI Activation—The assay was done as
described (26) with minor modifications. In a microtiterplate,
40 l of reaction mixture, 20 l of TAFI (100 nM), and 20 l of
rSclA/AP/M41 or rSclB/AP/M41 (0–0.45 M) weremixed and
prewarmed to 37 °C. The reaction mixture was composed of
P-enolpyruvate (2 mM) (all concentrations are final concentra-
tions in the assay), ATP (2.7 mM), NADH (0.5 mM), arginine
kinase (21 units/liter), pyruvate kinase/dehydrogenase, and
hippuryl-arginine (5 mM). The activation mixture contained
thrombin (8 nM), thrombomodulin (16 nM), and CaCl2 (5 mM)
or plasmin (0.36 units/ml). Volumes were adjusted with 20 mM
Hepes, pH 7.4, 0.01% Tween 20. The reactions were started by
adding 20 l of TAFI (100 nM). TAFI activation was followed
over time as a loss of NADH absorbance at 340 nm in a Ther-
momax microplate reader (Molecular Devices Corp., Menlo
Park, CA).
Clot-Lysis Assay—The clot-lysis assay was performed
essentially as described previously (27). Briefly, 47 l of cit-
rated, pooled, human plasma (pooled normal plasma) was
mixed with various concentrations of TAFI and rSclA/AP/
M41 or rSclB/AP/M41 (0–0.45 M) (all concentrations are
final concentrations in the assay) in a 96-well microtiter
plate. The experiments were done in the presence or absence
of carboxypeptidase inhibitor (12 M). The volumes were
adjusted to 65 l with HBS (25 mM Hepes, 137 mM NaCl, 3.5
mM KCl, pH 7.4) containing 0.1% (w/v) bovine serum albu-
min. A mixture (35 l) of a thousand-fold dilution of
Innovin, CaCl2 (17 mM), and recombinant tissue-type plas-
minogen activator (actilyse, 0.3 ng/ml) in HBS/0.1% (w/v)
bovine serum albumin, was added to the plasma and turbid-
ity was measured in time at 37 °C at 405 nm in a Thermomax
microplate reader (Molecular Devices). The clot-lysis time
was defined as the time difference between half-maximal
lysis and half-maximal clotting.
RESULTS
TAFI Binds to Collagen-like Surface Proteins from S. pyogenes—
To investigate the interaction between TAFI and streptococci,
the binding of 125I-TAFI to twelve different streptococcal sero-
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types was tested. Fig. 1 shows that the strains displayed varying
degrees of TAFI binding, with the AP41 strain being the most
efficient. Based on these results, the AP41 strain was chosen for
further characterization. To identify the streptococcal recep-
tor(s) involved in TAFI binding, surface proteins of the AP41
strain were solubilized with CNBr and incubated with TAFI
immobilized to Sepharose. Following a washing step, bound
proteins were eluted from the column, separated on SDS-
PAGE, and visualized byCoomassie staining. Fig. 2A shows that
a protein with an apparent molecular mass of 35 kDa was
recovered. The band was excised from the gel and further pro-
cessed by internal sequencing. Two peptides were generated,
both of which shared 90% homology with streptococcal collag-
en-like surface protein A (SclA) from an M41 strain (Table 1).
All group A streptococcal serotypes tested so far carry the
genes coding for SclA and SclB. As previous studies have
shown that the extracellular domains of the two proteins
differ significantly from each other and also vary within sero-
types, we decided to sequence both genes from the AP41
strain. As expected, the results show that the deduced nucle-
otide sequences of the two peptides (Table 1) were found in
SclA, but not in SclB.
To study the interaction between Scls and TAFI at the pro-
tein level, the extracellular part of SclA (rSclA/AP/M41) and
SclB (rSclB/AP/M41) from theAP41 strainwere recombinantly
expressed in E. coli and purified as described under “Experi-
mental Procedures.” Fig. 2B shows that the apparent molecular
masses of the two proteins were slightly higher than expected,
which was also reported when recombinantly expressed Scls
from other serotypes were examined by SDS electrophoresis
(3). Binding of TAFI to purified Scls was studied using the BIA-
core biosensor system. Analysis of the binding curves (Fig. 3, A
andB) showed that the interactions did not follow a one-to-one
stoichiometry model. The KD for steady state binding of TAFI
to SclA was 215  31 nM and to SclB 253  37 nM. For further
binding studies, rSclA/AP/M41 and rSclB/AP/M41 were
immobilized on a polyvinylidene difluoride membrane and
probed with 125I-TAFI. Moreover, SclA from the M41 strain
6183 (rSclA/176/M41) and the M28 strain 6274 (rSclA/161/
M28) as well as SclB from that M28 strain (rSclB/163/M28)
were also applied to themembrane.After awashing step, bound
125I-TAFI was detected by exposing the membrane to an x-ray
film. Fig. 3C shows that rSclA/AP/M41 binds more efficiently
to TAFI than rSclB/AP/M41. Interestingly, rSclA/176/M41
derived from another M41 strain bound TAFI to a similar
degree as rSclA/AP/M41, whereas rSclA/161/M28 and rSclB/
163/M28 showed no interaction. The latter observation is in
accordance with the finding that streptococci of the AP28
strain displayed only poor TAFI binding properties (Fig. 1). To
further establish the role of Scls in the binding of TAFI to S.
pyogenes, AP41 bacteria were incubated with 125I-TAFI in the
absence or presence of recombinant Scls. As a control, the sur-
face protein PAB from Finegoldiamagnawas used. PAB had no
influence on TAFI binding, whereas rSclA/AP/M41 and rSclB/
AP/M41 reduced TAFI binding 84 and 42%, respectively (Fig.
3D). No additional effect was seen with both proteins in com-
bination (data not shown).
To visualize the interaction of rSclA/AP/M41 and rSclB/AP/
M41 with TAFI, negative staining and transmission electron
microscopy were employed. Fig. 4, A and C, shows that rSclA/
AP/M41displayed a characteristic lollipop-like structurewith a
globular head and a tail as has also been described for other
Scls (9, 23), whereas TAFI had a horseshoe-like shape (Fig. 4,
FIGURE 1. Binding of TAFI to S. pyogenes. Twelve different strains of S. pyo-
genes, 2  109 CFU/ml, were incubated with 125I-TAFI for 1 h at room temper-
ature. Cells were washed, and the amount of radiolabeled protein that
remained bound to the bacteria was determined in a  counter.
FIGURE 2. Isolation of a TAFI-binding protein from S. pyogenes. A, surface
proteins from the AP41 strain of S. pyogenes were solubilized with CNBr as
described under “Experimental Procedures” and incubated with TAFI-cou-
pled Sepharose. After washing the Sepharose with PBS, bound proteins were
eluted and analyzed on SDS-PAGE. The figure shows a Coomassie-stained
SDS-PAGE gel with solubilized surface proteins from AP41 (lane 1) and eluted
proteins from the TAFI-coupled Sepharose (lane 2). The arrow indicates the
protein band that was subjected to internal sequencing. B, SclA and SclB from
the AP41 strain were cloned and expressed in E. coli and analyzed by SDS-
PAGE followed by Coomassie staining.
TABLE 1
Internal sequence analysis of TAFI-binding protein
Amino acid sequence Data base matcha
Internal peptide 1 SclA from S. pyogenes (serotype M41)
DTGAQGPVGPQ ETGAQGPVGPQ (positions 159–169)
Internal peptide 2 SclA from S. pyogenes (serotype M41)
GLPGLPGLPG GLTGLPGLPG (positions 134–143)
aSolubilized surface proteins from AP41 bacteria were incubated with TAFI-cou-
pled Sepharose, followed by extensive washing and elution of bound proteins. A
35-kDa protein was identified and analyzed by internal sequencing. Two peptide
sequenceswere generated andmatched against streptococcal proteins in a BLAST
search.
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B and E). When incubating TAFI with rSclA/AP/M41, the
carboxypeptidase was frequently (95%) localized close to
the heads of SclA (Fig. 4, D and F), and this was also found
when the interaction between rSclB/AP/M41 and TAFI was
investigated (data not shown). Interestingly, similar findings
were recently reported when the binding of ApoB100 to SclA
was analyzed (9).
S. pyogenes Strain AP41 Binds Plasmin and Thrombin to its
Surface—Under physiological conditions, TAFI can be acti-
vated by plasmin or the thrombin-thrombomodulin complex
(12, 13). The binding of plasmin/
ogen to various streptococcal
strains, including the AP41 strain
(28), is well established and has been
described earlier by many other
groups (29–31). However, the
interaction between Streptococci
and (pro)thrombin has been less
investigated, and to our knowledge
all binding studies conducted so far
showed that (pro)thrombin had no
affinity for the streptococcal strains
tested (31, 32). Thus, to investigate
whether activation of TAFI at the
bacterial surface can be induced by
recruited plasmin or thrombin-
thrombomodulin, we studied the
interaction of 125I-plasmin or 125I-
thrombin with AP41 bacteria. Fig.
5A shows that 125I-plasmin binds
avidly to the bacteria. In addition, an
interaction with 125I-thrombin was
observed. In both cases the binding
was displaceable by the addition of
unlabeled plasmin and thrombin,
respectively (Fig. 5, B and C). 50%
displacement occurred at concen-
trations around 30 g/ml for plas-
min and 300 g/ml for thrombin,
which would correlate to KD values
of 0.3 and 8 M, respectively.
Taken together, the results demon-
strate that not only TAFI, but also
two TAFI activators, namely plas-
min and thrombin, bind to the sur-
face of AP41 bacteria.
TAFI Is Cleaved by Plasmin and
Thrombin-Thrombomodulin at the
Bacterial Surface—TAFI activation
by plasmin or the thrombin-throm-
bomodulin complex occurs by the
removal of a 19-kDa activation pep-
tide from the amino-terminal part
of the protein. The resulting 36-kDa
active carboxypeptidase (TAFIa)
has a very short half-life (5 min)
because of a conformational reor-
ganization that drives the enzyme
into its inactive form (TAFIai). Further processing by plas-
min or the thrombin-thrombomodulin complex leads then
to the generation of smaller inactive fragments (13, 20). To
analyze whether streptococcal-bound TAFI can be cleaved
by a similar mechanism as described above, AP41 bacteria
were incubated with 125I-TAFI in the presence of increasing
concentrations of plasmin or thrombin-thrombomodulin.
After a short incubation time, bacteria were washed and pro-
teins recovered from the bacterial surface were separated on
SDS-PAGE. As control, 125I-TAFI was incubated by plasmin
FIGURE 3. TAFI binds to SclA and SclB. A and B, overlay plots of the binding of TAFI to immobilized SclA
(A) and SclB (B) using plasmon resonance spectroscopy. C, different concentrations of recombinant Scls
from two M41 strains (rSclA/AP/M41, rSclB/AP/M41, and rSclA/176/M41), and rScls from one M28 strain
(rSclA/161/M28 and rSclB/163/M28) were immobilized on a polyvinylidene difluoride membrane and
incubated with 125I-TAFI. Unbound TAFI was removed by a washing step, and the membrane was exposed
to an x-ray film. D, bacteria were incubated with 125I-TAFI in the presence or absence of 40 g/ml SclA,
SclB, or protein PAB. Statistical analysis (n  3) was performed using Student’s t-test (un-paired, two-
tailed). ***, p  0.001.
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or thrombin-thrombomodulin in the absence of bacteria.
Fig. 6,A and B, shows that treatment of bacteria-bound TAFI
with plasmin or thrombin-thrombomodulin leads to the
generation of a 36-kDa fragment that was also seen when
TAFI was cleaved in solution. To verify that cleavage occurs
at the bacterial surface, AP41 bacteria were preincubated
with plasmin or thrombin-thrombomodulin. Unbound pro-
teins were removed by a washing step, and bacteria were
incubated with 125I-TAFI for 30 min (plasmin) and 15 min
(thrombin-thrombomodulin). Thereafter, 125I-TAFI that
was recovered from the bacterial surface or remained in
solution was analyzed by SDS-PAGE. Fig. 6C shows that
TAFI processing occurred at the bacterial surface, but not in
solution. These findings implicate that bacteria-bound TAFI
is susceptible to cleavage by its two most important
activators.
The Physiologic Activity of TAFI Is Not Inhibited by SclA or
SclB—To investigate the influence of rScls on the activation
profile of TAFI, TAFI activation by thrombin-thrombomodu-
lin or plasmin was followed over time. At the concentrations
tested (0–0.45 M), neither rSclA/AP/M41 nor rSclB/AP/M41
had any influence on the activation profile (data not shown). In
addition, theTAFIa half-lifewas not changed by the presence of
rScls (0–0.18M) (data not shown). Based on these findings we
next wanted to investigate whether the rScls affected the
fibrinolytic action of TAFI. To this end, the effect of rScls was
studied in a clot-lysis test. In these assays, clotting of normal
pooled plasma supplemented with various concentrations of
rSclA/AP/M41 or rSclB/AP/M41 was initiated by tissue factor,
and fibrinolysis was initiated by recombinant tissue plasmino-
gen activator. Clot-lysis times were determined in the presence
orabsenceofacarboxypeptidase inhibitor tovisualize theTAFI-
dependent prolongation. The results show that the clot-lysis
times of plasma were not influenced by the presence of rScls
(Fig. 7). Taken together, these experiments demonstrate that
binding of TAFI to rSclA/AP/M41 and rSclB/AP/M41 does not
affect TAFI activation, TAFIa stability, or the anti-fibrinolytic
potential of TAFI, whichmay point to an important function of
bacteria-bound TAFI in the regulation of the inflammatory
host response.
DISCUSSION
Over the years, a number of host-pathogen interactions have
been described to be triggered by proteolytic-driven cascades
(33, 34). Based on the intensity of activation, these systems can
either clear an infection or promote pathological inflammatory
reactions (35). Typical examples are complement, coagulation,
and fibrinolysis, which are normally involved in host defense
during infection but can also cause deleterious and sometimes
life-threatening complications once they are activated in a sys-
temic manner. Thus, the study of these systems in relation to
their activation by invading pathogens may lead to a better
understanding of how a normally harmless infection can evoke
serious conditions in the human host. For instance, many bac-
terial pathogens have been shown to utilize the proteolytic sys-
tems of the host to establish an infection. Probably the best
studied human proteinase in this respect is plasminogen, which
apart from S. pyogenes also interacts with many other bacterial
FIGURE 4. Electron microscopy of rSclA/AP/M41 and TAFI. Representa-
tive fields of rSclA/AP/M41 (A) and TAFI (B) are visible after negative stain-
ing. Selected molecules of rSclA/AP/M41 (C) and TAFI (E) are shown at
higher magnification. D and F, TAFI binds in proximity to the globular
domain of rSclA/AP/M41. Arrowheads indicate globular domains of rSclA/
AP/M41, and arrows point to TAFI molecules. E and F, right panels, inter-
pretative presentations in pseudocolors of rSclA/AP/M41 (green) and TAFI
(red) are shown. Scale bars, 50 nm (A and B), 30 nm (C and D), and 10 nm (E
and F).
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species, including Borrelia burgdorferi, E. coli, Salmonella
enteritidis, Yersinia pestis, and the Neisseria species gonor-
rhoeae and meningitides (34). Activation of plasminogen is a
critical step in the progression of an infection, and several
modes of actions for different bacteria have been described.
FIGURE 5. AP41 bacteria bind plasmin and thrombin. A, serial dilutions of
AP41 bacteria were incubated with 125I-plasmin (black line) or 125I-thrombin
(gray line) for 1 h, followed by a washing step to remove unbound ligand.
Bacteria were centrifuged, and the amount of radiolabeled protein in the cell
pellet was determined with a  counter. The figure shows the means and S.D.
of three independently performed experiments. B and C, AP41 bacteria were
incubated for 1 h with 125I-plasmin (B) or 125I-thrombin (C) in the presence of
varying concentrations of the corresponding unlabeled ligand. Cells were
washed, and the radioactivity of the cell pellets was thereafter determined as
described above. The figure shows a representative experiment out of four,
each done in duplicate.
FIGURE 6. TAFI is cleaved by plasmin and thrombin-thrombomodulin at
the bacterial surface. AP41 bacteria were incubated with 125I-TAFI in the
absence or presence of plasmin (A) or thrombin-thrombomodulin (B) for 20 or
10 min, respectively. Bacteria were then washed, and proteins bound to the
bacterial surface were eluted and separated on SDS-PAGE. 125I-TAFI was visu-
alized by exposing the gel to an x-ray film. White arrowheads indicate intact
TAFI, whereas black arrowheads point to cleaved TAFI of 36, 25, and 11 kDa.
The figure shows representative results from at least three independently
performed experiments. C, AP41 bacteria were preincubated with plasmin,
thrombin-thrombomodulin, or left untreated. After a washing step to remove
unbound protein, bacteria were incubated with 125I-TAFI for 30 min (plasmin)
and 15 min (thrombin-thrombomodulin), respectively. Bacteria-bound 125I-
TAFI (B) and 125I-TAFI in solution (S) were analyzed by SDS-PAGE. As a control,
125I-TAFI before treatment was used (far left panel).
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While species such as S. pyogenes and Y. pestis express plas-
minogen-activating proteins (streptokinase and protein Pla,
respectively), others such as B. burgdorferi, Salmonella enterit-
idis, and E. coli recruit tissue plasminogen activator or uroki-
nase-type plasminogen activator from the host for this purpose
(34). Importantly, studieswith S. pyogenes,B. burgdorferi, and S.
aureus have demonstrated that plasmin, mobilized to the bac-
terial surface, is protected from inhibition by host proteinase
inhibitors, in particular 2-antiplasmin, resulting in a long last-
ing surface-associated enzymatic activity (29, 36, 37). The bind-
ing of plasmin/ogen to the streptococcal surface is well docu-
mented and involves M andM-like proteins (30, 38), -enolase
(39), and glyceraldehyde-3-phosphate dehydrogenase (40).
Whereas some M proteins bind plasminogen indirectly via
fibrinogen (38), other strains express an M-like protein called
PAM (plasminogen-binding groupA streptococcalM-like pro-
tein) that binds plasminogen directly with high affinity (30).
Notably, the strains that displayed the highest TAFI binding (M
type 41 and 53) were also PAM-expressing strains (28). Bacte-
rial interactions with pro/thrombin, on the other hand, are less
investigated, but it is well established that S. aureus secretes a
staphylocoagulase that interacts with thrombin without prote-
olysis (41). Both plasmin and thrombin have in common that
they are important physiologic activators of TAFI and, of note
for the present study, they assemble in their active forms at the
surface of AP41 bacteria. In the present study, we described for
the first time that TAFI binds to S. pyogenes by interacting with
the streptococcal collagen-like surface proteins SclA and SclB.
Importantly, bacteria do not have the machinery to activate
surface-bound TAFI, and they therefore have to recruit natural
activators of TAFI. The finding that TAFI is assembled with its
activators plasmin and thrombin at the streptococcal surface
implies that potentially high concentrations of activated TAFI
may be obtained locally at the site of infection. They also sug-
gest that TAFI activation can be regulated by bacteria via, for
instance, streptokinase-activated, bacteria-bound plasmin.
Activated TAFI is mostly known as an inhibitor of fibrinolysis.
Notably, previous studies have shown that S. pyogenes bacteria
adhering to epithelial cells are coatedwith a fibrin network (32).
It can therefore be speculated that the blood clot forms a shield
that protects the bacterium from the immune defense systems
of the host and that the recruitment and activation of TAFI on
the bacterial surface would help stabilize the clot. Moreover,
activation of complement, coagulation, and fibrinolysis occurs
by limited proteolysis and often involves the cleavage of anArg-
Ile or a Lys-Ile bond. Thus, many peptides involved in these
processes, such as the anaphylatoxins C3a and C5a, bradykinin
and kallidin, as well as fibrinopeptide B have an arginine at their
carboxyl terminus. As the generation of these peptides is
induced in response to infection, it is tempting to speculate that
bacteria-bound TAFI is used as a tool to modulate the host
response. Taken together, the present study shows that TAFI is
bound to AP41 bacteria via SclA and SclB and can be converted
into its active fragment by recruited plasmin and thrombin.
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